Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...

BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease. Potential treatments typically target a key mutated oncogene called ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal ...

Tiny circles called ecDNA are critical in cancer development and drug resistance. An international team publishes landmark studies detailing new findings and potential therapies. A trio of research ...

Scientists have demonstrated a creative new way to kill cancer cells effectively, with few side effects. Gluing two particular proteins together tricks the tumors into destroying themselves. Cells in ...

Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer Precision oncology in non–small ...

Pancreatic cancer remains one of the deadliest cancers, with survival rates showing little improvement over decades and projections placing it as the second leading cause of cancer deaths by 2030.